Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hebei Ruixing Pharmaceutical Co., Ltd. is a leading Chinese pharmaceutical company specializing in the research, development, and large-scale production of glycine and its derivatives. Established in 1998 and based in Shijiazhuang, the company has grown into one of the world's largest manufacturers of pharmaceutical-grade glycine, an essential amino acid used in intravenous infusions, nutritional supplements, and as a key intermediate for various pharmaceutical products. Ruixing operates state-of-the-art manufacturing facilities that comply with international quality standards, including GMP and ISO certifications. The company serves a global clientele, providing high-purity chemical products for the healthcare, food, and industrial sectors. Its business model focuses on high-purity chemical synthesis and the supply of essential pharmaceutical raw materials to the global market.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Ruixing Pharmaceutical.